176 related articles for article (PubMed ID: 37553607)
1. COVID-19 Vaccination and Gout Flare Risk in Patients With Infrequent or Frequent Flares: A Prospective Cohort Study.
He Y; Xue X; Dalbeth N; Terkeltaub R; Chen Y; Yan F; Pang L; Li X; Yuan X; Cheng X; Li C; Sun M
Arthritis Care Res (Hoboken); 2024 Jan; 76(1):131-139. PubMed ID: 37553607
[TBL] [Abstract][Full Text] [Related]
2. Colchicine prophylaxis is associated with fewer gout flares after COVID-19 vaccination.
Lu J; He Y; Terkeltaub R; Sun M; Ran Z; Xu X; Wang C; Li X; Hu S; Xue X; Yan F; Zhang H; Yin H; Shi Y; Dalbeth N; Li C
Ann Rheum Dis; 2022 Aug; 81(8):1189-1193. PubMed ID: 35277390
[TBL] [Abstract][Full Text] [Related]
3. Latent Class Growth Analysis of Gout Flare Trajectories: A Three-Year Prospective Cohort Study in Primary Care.
Watson L; Belcher J; Nicholls E; Muller S; Mallen C; Roddy E
Arthritis Rheumatol; 2020 Nov; 72(11):1928-1935. PubMed ID: 32767502
[TBL] [Abstract][Full Text] [Related]
4. Elevated serum CA72-4 predicts gout flares during urate lowering therapy initiation: a prospective cohort study.
Hu S; Sun M; Li M; Xue X; Terkeltaub R; Wang C; Wang M; Lu J; Ran Z; Li H; Ji A; Sun W; Li X; He Y; Liu Z; Zhang H; Wang X; Ji X; Dalbeth N; Li C
Rheumatology (Oxford); 2023 Jul; 62(7):2435-2443. PubMed ID: 36409036
[TBL] [Abstract][Full Text] [Related]
5. Post-hoc analysis of pegloticase pivotal trials in chronic refractory gout: relationship between fluctuations in plasma urate levels and acute flares.
Mandell BF; Fields TR; Edwards NL; Yeo AE; Lipsky PE
Clin Exp Rheumatol; 2021; 39(5):1085-1092. PubMed ID: 33427618
[TBL] [Abstract][Full Text] [Related]
6. Risk of gout flares after COVID-19 vaccination: A case-crossover study.
Li H; Dalbeth N; Wallace ZS; Sparks JA; Li X; Zeng C; Wang Y; Xie D; Lei G; Wei J; Zhang Y
Semin Arthritis Rheum; 2022 Oct; 56():152059. PubMed ID: 35797765
[TBL] [Abstract][Full Text] [Related]
7. Gout during the SARS-CoV-2 pandemic: increased flares, urate levels and functional improvement.
García-Maturano JS; Torres-Ordaz DE; Mosqueda-Gutiérrez M; Gómez-Ruiz C; Vázquez-Mellado A; Tafoya-Amado A; Peláez-Ballestas I; Burgos-Vargas R; Vázquez-Mellado J
Clin Rheumatol; 2022 Mar; 41(3):811-818. PubMed ID: 34822044
[TBL] [Abstract][Full Text] [Related]
8. One- and 2-year flare rates after treat-to-target and tight-control therapy of gout: results from the NOR-Gout study.
Uhlig T; Karoliussen LF; Sexton J; Kvien TK; Haavardsholm EA; Perez-Ruiz F; Hammer HB
Arthritis Res Ther; 2022 Apr; 24(1):88. PubMed ID: 35443675
[TBL] [Abstract][Full Text] [Related]
9. The GOUT-36 prediction rule for inpatient gout flare in people with comorbid gout: derivation and external validation.
Jatuworapruk K; Grainger R; Dalbeth N; Lertnawapan R; Hanvivadhanakul P; Towiwat P; Shi L; Taylor WJ
Rheumatology (Oxford); 2022 Apr; 61(4):1658-1662. PubMed ID: 34297058
[TBL] [Abstract][Full Text] [Related]
10. Fluctuation and change of serum urate levels and flares in gout: results from the NOR-Gout study.
Uhlig T; Karoliussen LF; Sexton J; Kvien TK; Haavardsholm EA; Perez-Ruiz F; Hammer HB
Clin Rheumatol; 2022 Dec; 41(12):3817-3823. PubMed ID: 36316609
[TBL] [Abstract][Full Text] [Related]
11. Cohort study investigating gout flares and management in UK general practice.
Finnikin S; Mallen CD; Roddy E
BMC Prim Care; 2023 Nov; 24(1):246. PubMed ID: 37993770
[TBL] [Abstract][Full Text] [Related]
12. Prevalence, Risk Factors, and Outcomes of Gout Flare in Patients Hospitalized for PCR-Confirmed COVID-19: A Multicenter Retrospective Cohort Study.
Jatuworapruk K; Satpanich P; Robinson PC; Grainger R
J Rheumatol; 2023 Apr; 50(4):556-563. PubMed ID: 36379566
[TBL] [Abstract][Full Text] [Related]
13. UltraSound evaluation in follow-up of urate-lowering therapy in gout phase 2 (USEFUL-2): Duration of flare prophylaxis.
Ebstein E; Forien M; Norkuviene E; Richette P; Mouterde G; Daien C; Ea HK; Brière C; Lioté F; Petraitis M; Bardin T; Ora J; Dieudé P; Ottaviani S
Joint Bone Spine; 2020 Dec; 87(6):647-651. PubMed ID: 32979555
[TBL] [Abstract][Full Text] [Related]
14. Risk of gout flares after vaccination.
Lai SW; Kuo YH; Liao KF
Ann Rheum Dis; 2021 Aug; 80(8):e137. PubMed ID: 31422355
[No Abstract] [Full Text] [Related]
15. Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study.
Yamanaka H; Tamaki S; Ide Y; Kim H; Inoue K; Sugimoto M; Hidaka Y; Taniguchi A; Fujimori S; Yamamoto T
Ann Rheum Dis; 2018 Feb; 77(2):270-276. PubMed ID: 29102957
[TBL] [Abstract][Full Text] [Related]
16. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study.
Schumacher HR; Evans RR; Saag KG; Clower J; Jennings W; Weinstein SP; Yancopoulos GD; Wang J; Terkeltaub R
Arthritis Care Res (Hoboken); 2012 Oct; 64(10):1462-70. PubMed ID: 22549879
[TBL] [Abstract][Full Text] [Related]
17. How flare prevention outcomes are reported in gout studies: A systematic review and content analysis of randomized controlled trials.
Stewart S; Tallon A; Taylor WJ; Gaffo A; Dalbeth N
Semin Arthritis Rheum; 2020 Apr; 50(2):303-313. PubMed ID: 31796212
[TBL] [Abstract][Full Text] [Related]
18. Monosodium urate burden assessed with dual-energy computed tomography predicts the risk of flares in gout: a 12-month observational study : MSU burden and risk of gout flare.
Pascart T; Grandjean A; Capon B; Legrand J; Namane N; Ducoulombier V; Motte M; Vandecandelaere M; Luraschi H; Godart C; Houvenagel E; Norberciak L; Budzik JF
Arthritis Res Ther; 2018 Sep; 20(1):210. PubMed ID: 30223875
[TBL] [Abstract][Full Text] [Related]
19. Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial.
Stamp L; Horne A; Mihov B; Drake J; Haslett J; Chapman PT; Frampton C; Dalbeth N
Ann Rheum Dis; 2023 Dec; 82(12):1626-1634. PubMed ID: 37652661
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare.
Janssen CA; Oude Voshaar MAH; Ten Klooster PM; Vonkeman HE; van de Laar MAFJ
Clin Rheumatol; 2019 Aug; 38(8):2233-2239. PubMed ID: 31030363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
